StockData
Rezolute, Inc. logo

Rezolute, Inc. (RZLT) stock

RZLTNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$3.65−0.22 (-5.56%)

Close on Nov 13, 2026Market cap $353.52MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026

Valuation

Market cap
$353.52M
P/E ratio
–
Price to sales
–
Price to book
4.11
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$77.94M
EPS, diluted
-$0.76
Book value per share
$0.82
Diluted shares
105M

Trading

Next earnings
Feb 11, 2027 (estimated, after the close)
Previous close
$3.87
Open
$4.56
Day's range
$3.60 – $4.61
Volume
5,736,255
Average volume (20 days)
1,491,886
Index membership
Russell 2000 (since Jun 2025)
Beta (5 years)
0.83
52-week range
$1.07 – $11.16
RSI (14 days)
41.1
Volatility (1 year)
127.2%
Relative volume
3.94×
WACC
9.3%

On 1 of our idea list: Most shorted (a warning list)

Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2013, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

PeriodRZLTS&P 500DifferenceRZLT per yearS&P 500 per year
1 month-20.7%-3.0%−17.7 pts
3 months-20.5%-2.8%−17.8 pts
Year to date+54.9%+11.5%+43.4 pts
1 year-63.2%+13.5%−76.7 pts
3 years+328.5%+77.7%+250.8 pts+62.4%+21.1%
5 years-42.0%+72.6%−114.6 pts-10.3%+11.5%
10 years-93.5%+308.2%−401.6 pts-23.9%+15.1%

Fifteen years at a glance

Fiscal years 2010 to 2026 and trailing twelve months, USD

Operating income

-$82.53M

Net income

-$77.94M

EPS, diluted

-$0.76

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Rezolute filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Rezolute

Pharmaceutical Preparations

Rezolute, Inc. is a late-stage rare disease biopharmaceutical company focused on developing therapies for refractory and debilitating hypoglycemia associated with forms of hyperinsulinism. The company's principal clinical asset is ersodetug, an intravenously administered human monoclonal antibody designed to down-modulate insulin receptor activity and normalize blood glucose levels. Its pipeline targets conditions such as congenital hyperinsulinism in pediatric patients and tumor hyperinsulinism caused by neuroendocrine islet cell tumors and non-islet cell tumors. Potential end users and target recipients include pediatric individuals suffering from congenital hyperinsulinism, as well as hospitalized or adult patients with inoperable or metastatic tumors experiencing severe hypoglycemia.

Company profile, executives and history

Rezolute stock: common questions

What is Rezolute's stock price?

RZLT closed at $3.65 on Nov 13, 2026, down 5.56% on the day. Over the past 52 weeks it traded between $1.07 and $11.16.

What is Rezolute's market cap?

Rezolute was worth $353.52M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.

What is RZLT's P/E ratio?

Rezolute lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.76), so it has no meaningful P/E ratio.

Does Rezolute pay a dividend?

No. Rezolute has not paid a cash dividend over the last twelve months.

When does Rezolute report earnings next?

Rezolute is expected to report Q2 FY2027 results on Feb 11, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.

How has RZLT stock performed over the past year?

Including dividends, RZLT returned -63.2% over the past year, against +13.5% for the S&P 500.

How many RZLT shares are sold short?

18M shares were sold short at the latest FINRA report, 21.44% of the float, or 14.9 days of average trading volume.

Who are Rezolute's competitors?

Companies most similar to Rezolute by business, industry and size include XERS, VRDN, RYTM, BMEA, ETON.

See a number that looks wrong?